主要文件

查看所有文档

Y0000675

吉西他滨

Name: 吉西他滨
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

别名:

2′;-脱氧-2′,2′-二氟胞苷; dFDC, Gemzar (Lilly), LY-188011, dFdC, dFdCyd

登录查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:

C₉H₁₁F₂N₃O₄ · HCl

化学文摘社编号:

122111-03-9

分子量:

299.66

NACRES:

NA.24

PubChem Substance ID:

329831089

UNSPSC Code:

41116107

MDL number:

MFCD01735988

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

属性

grade

pharmaceutical primary standard

API family

gemcitabine

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

Cl.NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F

InChI

1S/C9H11F2N3O4.ClH/c10-9(11)6(16)4(3-15)18-7(9)14-2-1-5(12)13-8(14)17;/h1-2,4,6-7,15-16H,3H2,(H2,12,13,17);1H/t4-,6-,7-;/m1./s1

InChI key

OKKDEIYWILRZIA-OSZBKLCCSA-N

Gene Information

human ... POLA1(5422), POLA2(23649), POLD1(5424), POLD2(5425), POLD3(10714), POLD4(57804), POLE(5426), POLE2(5427), POLE3(54107), PRIM1(5557), PRIM2(5558), RRM1(6240), RRM2(6241), RRM2B(50484)

说明

General description

本品按现行药典规定交付。所有为支持本产品而提供的信息，包括SDS和任何产品信息单均由药典颁发机构制定并发布。如需进一步信息和支持，请访问现行药典网站。

Application

盐酸吉西他滨EP参考标准品设计用于欧洲药典规定的实验室测试。

Biochem/physiol Actions

吉西他滨是一种广泛使用的抗肿瘤药和抗代谢药。

吉西他滨是诊所和研究实验室中广泛使用的抗肿瘤药物。它是一种抗肿瘤药和抗代谢药。

Packaging

本品按照现行药典要求提供。有关当前单位数量，请见EDQM 参考目录。

Other Notes

可能适用相应的销售限制。

Still not finding the right product?

Explore all of our products under 吉西他滨

pictograms

GHS08

signalword

Danger

hcodes

H360

pcodes

P201 - P202 - P280 - P308 + P313 - P405 - P501

Hazard Classifications

Repr. 1B

存储类别

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助，请联系客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Anti-Bv8 antibody and metronomic gemcitabine improve pancreatic adenocarcinoma treatment outcome following weekly gemcitabine therapy.

Erez Hasnis et al.

Neoplasia (New York, N.Y.), 16(6), 501-510 (2014-06-25)

Weekly gemcitabine therapy is the major treatment offered for patients with pancreatic adenocarcinoma cancer; however, relative resistance of tumor cells to chemotherapy, rapid regrowth, and metastasis are the main causes of death within a year. Recently, the daily continuous administration

Rat N-ERC/mesothelin as a marker for in vivo screening of drugs against pancreas cancer.

Katsumi Fukamachi et al.

PloS one, 9(10), e111481-e111481 (2014-10-28)

Pancreatic ductal adenocarcinoma (PDA) is a highly lethal disease, which is usually diagnosed in an advanced stage. We have established transgenic rats carrying a mutated K-ras gene controlled by Cre/loxP activation. The animals develop PDA which is histopathologically similar to

Phase 1b study of the oral gemcitabine 'Pro-drug' LY2334737 in combination with capecitabine in patients with advanced solid tumors.

Jeffrey R Infante et al.

Investigational new drugs, 33(2), 432-439 (2015-02-03)

Background This Phase 1b study aimed to determine the recommended Phase 2 dose of LY2334737, an oral pro-drug of gemcitabine, in combination with capecitabine, an oral pro-drug of 5-fluorouracil, in patients with advanced solid tumors. In addition, pharmacokinetics (PK) and

查看所有相关文献

全球贸易项目编号

货号	GTIN
Y0000675	04061837577642